Introduction And Hypothesis: Comparison of the effects of trospium and solifenacin used for the treatment of overactive bladder (OAB) on intraocular pressure (IOP) and tear secretion.
Methods: This study was planned as a prospective study and was conducted at a single center between October 2014 and April 2016. OAB patients were included in the study following an ophthalmic examination, IOP measurement with an applanation tonometer, and tear secretion measurement with the Schirmer I test in the ophthalmology outpatient department. The patients were started with trospium 30 mg oral bid or solifenacin 5 mg oral qd. They were then followed up at the 4th and 12th weeks.
Results: A total of 225 OAB patients with a mean age of 47.80 (18-75) years were evaluated. The mean age was 47.41 ± 12.65 years in the trospium group (n = 104) and 48.14 ± 11.82 years in the solifenacin group (n = 121) with no statistically significant difference. When the two medications were compared, no statistically significant difference was observed at the 4th and 12th weeks in terms of IOP (p = 0.988, p = 0.822) and dry eye (p = 0.764, p = 0.581).
Conclusions: No statistically significant difference was observed between trospium and solifenacin in terms of their effects on IOP and tear secretion in OAB patients. We therefore concluded that the effects of trospium and solifenacin on IOP and tear secretion changes were similar in OAB patients without comorbidities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00192-020-04473-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in Medicare Coverage of Overactive Bladder Medications in the United States.
Urogynecology (Phila)
December 2024
From the Urogynecology and Reconstructive Pelvic Surgery, MedStar Washington Hospital Center/Georgetown University, Washington, DC.
Importance: Strong evidence demonstrates long-term cognitive decline associated with anticholinergics. While prevalent among older populations, medical management of overactive bladder (OAB) is dictated by insurance coverage rather than medical provider and patient preferences.
Objective: The aim of this study was to assess Medicare insurance plan coverage for select OAB medications and evaluate coverage of preferred medications to medications with a greater risk of cognitive dysfunction.
Long-term efficacy of Mirabegron-anticholinergic combination in paediatric neurogenic bladder.
J Pediatr Urol
January 2025
Department of Women and Children's Health, School of Life Course Sciences, Kings College London, London, UK; Children's Bladder Service, Evelina London Children's Hospital, Westminster Bridge Road, London, SE1 7EH, UK.
Introduction: The Mirabegron-anticholinergic (MAC) combination has proven effective as a step-up strategy in managing paediatric neurogenic bladder following anticholinergic medication and botulinum toxin (BTX) therapy. This study assesses the long-term efficacy of MAC in children with neurogenic bladder.
Patients And Methods: A retrospective chart review was conducted from 2015 to 2023, including consecutive paediatric patients receiving Mirabegron (25/50 mg) with an anticholinergic agent (solifenacin 16, tolterodine 7, oxybutynin 7, trospium 1).
Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study.
BMJ Med
November 2024
Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.
Article Synopsis
- The study aimed to assess the risk of developing dementia associated with different anticholinergic drugs prescribed for overactive bladder among older adults in England.
- Utilizing data from the Clinical Practice Research Datalink, researchers conducted a nested case-control study involving over 170,000 patients diagnosed with dementia, alongside matched controls without dementia.
- Results indicated a slightly elevated risk of dementia (odds ratio of 1.18) linked to anticholinergic drug use, with a higher risk observed in men compared to women.
Safety and Efficacy of Trospium Chloride and Solifenacin in Stroke-Induced Neurogenic Lower Urinary Tract Dysfunction: A Randomized Controlled Trial.
Neurourol Urodyn
January 2025
Research Center for Evidence-Based Medicine, Iranian EBM Centre: A JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Article Synopsis
- The study evaluated the effectiveness of a 4-week treatment with Solifenacin and Trospium chloride for lower urinary tract symptoms (LUTS) in 206 stroke patients.
- Results showed that both medications significantly improved urinary symptoms and quality of life compared to placebo, with Solifenacin showing better outcomes and fewer side effects.
- The study highlights the importance of tailored treatments for LUTS in stroke patients, suggesting Solifenacin as a potentially safer and more effective option.
The impact of anticholinergics on cognitive function in patients with neurogenic lower urinary tract dysfunction: A narrative review.
Indian J Urol
April 2024
Department of Surgery, Western University, London, Ontario, Canada.
This narrative review discusses the relationship between anticholinergic medications and cognitive change specifically in patients with neurogenic lower urinary tract dysfunction (NLUTD). NLUTD is prevalent in various conditions, including spinal cord injury (SCI), spina bifida (SB), multiple sclerosis (MS), Parkinson's, stroke, and dementia and often requires anticholinergic overactive bladder (OAB) medications. In the general population, and among those with OAB, several studies have found a significant association between this class of medications and cognitive side effects, mostly when used for > 90 days.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!